Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796 - Wikidata - awgldk - TriplyDB

Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796

Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796

http://www.wikidata.org/entity/Q28193385

about

sameAs

1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.

P2860

Q35995199-EC19DFAA-7570-423F-B799-863FD6C45ACA

P2860

Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796

http://www.wikidata.org/entity/Q28193385

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Prevention of experimental car ...... a receptor antagonist CRL42796

@ast

Prevention of experimental car ...... a receptor antagonist CRL42796

@en

Prevention of experimental car ...... a receptor antagonist CRL42796

@nl

type

label

Prevention of experimental car ...... a receptor antagonist CRL42796

@ast

Prevention of experimental car ...... a receptor antagonist CRL42796

@en

Prevention of experimental car ...... a receptor antagonist CRL42796

@nl

prefLabel

Prevention of experimental car ...... a receptor antagonist CRL42796

@ast

Prevention of experimental car ...... a receptor antagonist CRL42796

@en

Prevention of experimental car ...... a receptor antagonist CRL42796

@nl

P1433

Q28193385-7FAD4BAC-109A-4A1F-98FD-CCAE168C1C8D

P1476

Q28193385-6F373C5E-26BC-46B4-840B-150CBE443393

P2093

Q28193385-3E27B70C-BCD0-4D00-81DD-CA607EC045BE

Q28193385-4BD9FA81-68DA-4BA4-9B75-0F7169D2CE9F

Q28193385-4DBBBF4F-1BBC-42DA-BA78-8B5F70F229B4

Q28193385-5B40DD12-4718-41B2-BBA7-6A51FDF928E0

Q28193385-E90B155D-877B-4829-B6EF-B349CE257BC8

Q28193385-F29D2069-CC7A-4F77-83FC-A1C7B56D4EBC

P2860

Q28193385-16942F4F-AF5D-4ACE-A972-777E8340DB9C

Q28193385-24BB3907-087C-4BFD-8606-F4C7D0BBDF73

Q28193385-551128DB-1D9C-4E23-9DB1-347F88EB90DF

Q28193385-89292194-FD49-4F11-A527-E9DC00BACF13

Q28193385-915E03B8-D3F8-4922-A418-D1A8BC5FA399

Q28193385-95272280-450A-477D-AD23-31C3640265B0

Q28193385-BB781A72-FDBC-42E6-AED4-3756AD59837B

Q28193385-CBE0AC83-F703-4D07-B410-B7FBBF7FF54E

Q28193385-F057E35A-CBCB-49C2-AEB0-E60E4B9EDD8A

Q28193385-F4CFE6F2-0976-412A-996E-3D2F2BF2CD73

P304

Q28193385-C2D20516-A2B6-42DE-BE59-1B6F118F77D7

P31

Q28193385-AF6FAD73-85F9-4977-BFE4-4211D5FC6148

P356

Q28193385-EC6DBA9A-C169-40ED-BD11-7BDC62B69AC2

P407

Q28193385-62567873-9B9F-415D-8E62-B95D807A0FBF

P433

Q28193385-2B1C7226-CB21-4A87-8ED7-9B5B7603262C

P478

Q28193385-F72863C3-0CD3-4315-B809-08167BF28909

P577

Q28193385-984B68C6-9857-43E6-AA57-AD30298F3BA0

P5875

Q28193385-EBED10F8-E4FF-414E-9AFB-F8D26E3E8C6C

P698

Q28193385-D3DA179B-AB96-443F-BFA7-E4C84E6BF0BE

P921

Q28193385-0FA2CDB5-04F7-4A8C-BBA2-CB07AD27710A

P932

Q28193385-3E478638-01C1-4E94-92A1-47AF13E496EF

P356

P1433

British Journal of Pharmacology

P1476

Prevention of experimental car ...... a receptor antagonist CRL42796

@en

P2093

Benedict R Lucchesi

http://www.w3.org/2001/XMLSchema#string

David E Willens

http://www.w3.org/2001/XMLSchema#string

Edward M Driscoll

http://www.w3.org/2001/XMLSchema#string

James K Hennan

http://www.w3.org/2001/XMLSchema#string

Thierry A Giboulot

http://www.w3.org/2001/XMLSchema#string

Ting-Ting Hong

http://www.w3.org/2001/XMLSchema#string

P2860

New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting.

Advances in antithrombotic therapy of acute myocardial infarction.

Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist

In vivo models of arterial thrombosis and thrombolysis.

A critical reappraisal of the bleeding time.

Ca2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex.

Isolation and characterization of a chymotryptic fragment of platelet glycoprotein IIb-IIIa retaining Arg-Gly-Asp binding activity.

P304

927-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0704744

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11267182

http://www.w3.org/2001/XMLSchema#string

P698

12110617

http://www.w3.org/2001/XMLSchema#string

P921

P932

1573408

http://www.w3.org/2001/XMLSchema#string